Afficher la couverture 'Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13 | Parigi, Tommaso Lorenzo' en grand format
/5

0 avis

Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13

Archive ouverte

Parigi, Tommaso Lorenzo | d'Amico, Ferdinando | Peyrin-Biroulet, Laurent | Danese, Silvio

Edité par CCSD ; Taylor & Francis -

International audience. Biologic drugs have significantly improved the treatment of ulcerative colitis (UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their high cost. Infliximab was the first biologic to be approved for inflammatory bowel diseases (IBD). After its patent expired other manufactures developed biosimilar versions, among which CT-P13, and licensed them thorough an expedite process.

Consulter en ligne

Suggestions

Du même auteur

Endoscopic Surveillance in Inflammatory Bowel Disease: The VIRTUE Is in High Definition

Archive ouverte | Parigi, Tommaso Lorenzo | CCSD

International audience. No abstract available

Defining difficult-to-treat inflammatory bowel disease: why and how

Archive ouverte | Danese, Silvio | CCSD

International audience

Do JAK inhibitors have a realistic future in treating Crohn’s disease?

Archive ouverte | Parigi, Tommaso Lorenzo | CCSD

International audience. No abstract available

Chargement des enrichissements...